Breast cancer oncogenes on the 8p11 amplicon.

描述（由申请人提供）：涉及染色体8 p11-p12的局灶性扩增发生在约15%的人类乳腺癌中。成纤维细胞生长因子受体1（FBFR 1）基因一直被认为是该位点的最佳候选癌基因。我们实验室开发的三种乳腺癌细胞系：SUM-44，SUM-52和SUM- 225具有以染色体8p11.2为中心的重叠扩增子。FGFR 1在这些细胞系中的两个中扩增，但仅在其中一个中过表达。映射到该区域的第二个基因，转化相关卷曲螺旋蛋白1（TACC 1），最近已被证明在一些乳腺癌细胞中过表达，并在NIH 3 T3细胞中具有转化活性。TACC 1在我们的所有三种细胞系中扩增并过表达。除了FGFR 1/TACC 1基因座之外，SUM-52和SUM-225细胞可能各自具有分别以8 p12和8q11.1为中心的不同扩增子。这些区域包含几个高度过表达的基因。因此，本提案的主要目的是研究8 p11-p12扩增子在人乳腺癌中的预后和预测意义，并鉴定其中可能是开发新疗法的良好靶点的基因。该项目的具体目标是：1）使用已知定位于各细胞系中基因扩增区域的基因探针，通过Southern印迹法完成SUM-44、SUM-52和SUM-225细胞系中8 p11-p12扩增子的精细定位，2）通过北方印迹法和RT-PCR检测各细胞系中扩增基因的表达水平，3）为了使用组织微阵列确定乳腺癌样本中8 p12 - 8 q11扩增子的不同区域和特定候选乳腺癌基因的扩增的预测和/或预后意义，四、通过转导候选基因，检测在三种乳腺癌细胞系中发现的扩增和过表达基因的机制意义转化到永生化的人乳腺上皮细胞中，并通过反义技术下调乳腺癌细胞中过表达的基因。因此，这些研究旨在为乳腺癌的一个重要子集定义新的和更好的预后和预测标志物，并鉴定因果相关基因，其产物可能是新疗法的良好靶点。

DESCRIPTION (provided by applicant): Focal amplifications involving chromosome 8p11-p12 occur in approximately 15% of human breast cancers. The fibroblast growth factor receptor 1 (FBFR1) gene has long been considered to be the best candidate oncogene at that locus. Three breast cancer cell lines developed in our lab; SUM-44, SUM-52 and SUM- 225, have overlapping amplicons centered around chromosome 8p11.2. FGFR1 is amplified in two of these cell lines, but is over expressed in only one of them. A second gene that maps to this region, transformation associated coiled-coiled protein 1 (TACC1), has recently been shown to be over expressed in some breast cancer cells and to have transforming activity in NIH3T3 cells. TACC1 is amplified and over expressed in all three of our cell lines. In addition to the FGFR1/TACC1 locus, SUM-52 and SUM-225 cells may each have distinct amplicons that center around 8p12 and 8q11.1 respectively. These regions contain several genes that are highly over expressed. Therefore, the broad aim of this proposal is to examine the prognostic and predictive significance of the 8p11-p12 amplicon in human breast cancer, and to identify genes therein that may be good targets for the development of novel therapeutics. The specific aims of this project are: 1) To complete the fine mapping of the 8p11-p12 amplicon in the SUM-44, SUM-52, and SUM-225 cell lines by Southern blotting using probes for genes known to map to the region of gene amplification in each line, 2) To examine the expression levels of the amplified genes in each cell line by northern blot and RT-PCR, 3) To determine the predictive and/or prognostic significance of amplification of distinct regions of the 8p12-8q11 amplicon, and of specific candidate breast cancer genes, in breast cancer specimens using tissue micro arrays, 4) To test the mechanistic significance of genes found to be amplified and over expressed in the three breast cancer cell lines by transduction of candidate genes into immortalized human mammary epithelial cells, and by antisense techniques to down-regulate over expressed genes in breast cancer cells. Thus, these studies are aimed at defining new and better prognostic and predictive markers for an important subset of breast cancer, and at identifying causally relevant genes the products of which could be good targets for novel therapeutics.